Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors.

Xiaohua Guo, Zhaowen Liu, Yizhou Zheng, Yamei Li, Linfu Li, Hai Liu, Zhixi Chen, Longhuo Wu

Drug design, development and therapy 2020

filter terms:

Transthyretin (TTR) is a tetrameric protein, and its dissociation, aggregation, deposition, and misfolding are linked to several human amyloid diseases. As the main transporter for thyroxine (T4) in plasma and cerebrospinal fluid, TTR contains two T4-binding sites, which are docked with T4 and subsequently maintain the structural stability of TTR homotetramer. Affected by genetic disorders and detrimental environmental factors, TTR degrades to monomer and/or form amyloid fibrils. Reasonably, stabilization of TTR might be an efficient strategy for the treatment of TTR-related amyloidosis. However, only 10-25% of T4 in the plasma is bound to TTR under physiological conditions. Expectedly, T4 analogs with different structures aiming to bind to T4 pockets may displace the functions of T4. So far, a number of compounds including both natural and synthetic origin have been reported. In this paper, we summarized the potent inhibitors, including bisaryl structure-based compounds, flavonoids, crown ethers, and carboranes, for treating TTR-related amyloid diseases and the combination modes of some compounds binding to TTR protein. © 2020 Guo et al.

Citation

Xiaohua Guo, Zhaowen Liu, Yizhou Zheng, Yamei Li, Linfu Li, Hai Liu, Zhixi Chen, Longhuo Wu. Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors. Drug design, development and therapy. 2020;14:1057-1081